Sugammadex

DB06206ApprovedInvestigationalSmall molecule

Sugammadex is a modified gamma cyclodextrin used to reverse neuromuscular blockade induced by vecuronium bromide and rocuronium bromide which are agents used for anesthesia. Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.

Mechanism: Sugammadex is a modified gamma-cyclodextrin which forms very tight water soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium > vecuronium >> pancuronium). Sugammadex creates a concentration gradient which favors movement of rocurionium from the neuromuscular junction into the plasma, which quickly reverses rocuronium-induced neuromuscular blockade. The free rocuronium in the plasma are then bound tightly to sugammadex, assisting the diffusion of the remaining rocuronium molecules out of the neuromuscular junction and increasing bound and free rocuronium in the plasma.
Curator reviewed
Primary indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients who are undergoing surgery.Curator reviewed · 2 structured indications
Formula / weight: C₇₂H₁₁₂O₄₈S₈ · 2002.12 g/mol (avg)
First approval: Canada, 2016 · United States, 2015 · European Union, 2020
Code names: MK-8616 · ORG-25969
Brand names: Bridion
Sugammadex Adroiq
Sugammadex Amomed
Sugammadex Fresenius Kabi
Sugammadex Mylan
Sugammadex Piramal

Resolves to

Compound

UNII361LPM2T56CAS343306-71-8ChEMBLCHEMBL5412674ChEBI90953PubChem6918585KEGGD05940

Clinical / RWD

RxNorm1726988ATCV03AB35

Structure

InChIKeyWHRODDIHRRDWEW-VTHZAVIASA-NSMILES

O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O

Targets

Q13936CACNA1C

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

104Drug interactionsStructured to mechanism, not free text

220Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

200Marketed productsAcross 11 countries and 86 labellers

1ATC codeIncluding every combination product, plus 9 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sugammadex, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account